UNIQURE N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.855 USD | +0.10% |
|
-1.32% | -28.43% |
| 08/05 | Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating | MT |
| 07/05 | UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 47.23M 51.25M 4.27B | Sales 2025 * | 83.38M 90.48M 7.53B | Capitalization | 217M 235M 19.58B |
|---|---|---|---|---|---|
| Net income 2024 * | -220M -239M -19.87B | Net income 2025 * | -171M -186M -15.45B | EV / Sales 2024 * | 3.12 x |
| Net cash position 2024 * | 69.35M 75.26M 6.26B | Net Debt 2025 * | 9.03M 9.8M 816M | EV / Sales 2025 * | 2.71 x |
| P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.3
x | Employees | 480 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on uniQure N.V.
More recommendations
More press releases
| 1 day | +0.10% | ||
| 1 week | -1.32% | ||
| Current month | +9.86% | ||
| 1 month | +0.52% | ||
| 3 months | -22.60% | ||
| 6 months | -28.01% | ||
| Current year | -28.43% |
1 week
4.75
5.18
1 month
4.255.19
Current year
4.257.12
1 year
4.2521.88
3 years
4.2538.80
5 years
4.2582.49
10 years
4.2582.49
| Managers | Title | Age | Since |
|---|---|---|---|
Matt Kapusta
CEO | Chief Executive Officer | 51 | 01/15/01 |
Christian Klemt
DFI | Director of Finance/CFO | 51 | 01/15/01 |
Pierre Caloz
COO | Chief Operating Officer | 52 | 17/21/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Post
BRD | Director/Board Member | 72 | 17/20/17 |
Jack Kaye
BRD | Director/Board Member | 80 | 15/16/15 |
| Director/Board Member | 61 | 14/17/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 11 M€ | -6.03% | - | |
| 0.76% | 14 M€ | -2.76% | ||
| 0.48% | 28 M€ | -0.70% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 4.845 | -0.10% | 20 122 |
| 20/24/20 | 4.85 | -3.19% | 524,633 |
| 17/24/17 | 5.01 | -1.18% | 372,197 |
| 16/24/16 | 5.07 | +0.20% | 347,654 |
| 15/24/15 | 5.06 | +3.05% | 462,888 |
Delayed Quote Nasdaq, May 21, 2024 at 07:26 pm IST
More quotes
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.
Calendar
18/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
4.465
EUR
Average target price
18.07
EUR
Spread / Average Target
+304.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.43% | 235M | |
| +9.46% | 115B | |
| +12.76% | 107B | |
| -13.38% | 22.31B | |
| -3.03% | 21.6B | |
| -5.26% | 18.23B | |
| -38.57% | 17.62B | |
| +7.46% | 14.26B | |
| +35.22% | 12.37B | |
| -26.46% | 8.28B |
- Stock Market
- Equities
- QURE Stock